

CONSTELLATION IMMUNOTHERAPY LIMITED

Unit 1233, 12/F, Star House, 3 Salisbury Road, Tsim Sha Tsui, Kowloon, Hong Kong

21 July 2020

ASX Market Announcement Office

Delivery via facsimile +61 (0)2 9347 0005

ASX Limited

20 Bridge Street

Sydney NSW 2000

CC: ANTERIS TECHNOLOGIES LTD ACN 088 221 078

formerly ADMEDUS LTD ACN 088 221 078

Toowong Tower

Level 3, 9 Sherwood Rd

Toowong QLD 4066

PO Box 1159, Milton 4064

T: +61 (0)7 3152 3200


F: +61 (0)7 3152 3299

Re: Notice of Ceasing to be a Substantial Holder (Form 605)

Dear Sir/Madam,

In accordance with section 671B of the *Corporations Act 2001* (Cth), we enclose a Notice of ceasing to be a substantial holder (Form 605) in respect of ANTERIS TECHNOLOGIES LTD ACN 088 221 078 formerly ADMEDUS LTD ACN 088 221 078.

Yours faithfully,



Fung Yuen Wong

Director of Constellation Immunotherapy Limited

Encl.

Form 605

Corporations Act 2001

Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme ANTERIS TECHNOLOGIES LTD formerly ADMEDUS LTD

ACN/ARSN ACN 088 221 078

1. Details of substantial shareholder (1)

Name Constellation Immunotherapy Limited, Everbest City Limited and Mr. Fung Yuen Wong

ACN/ARSN (if applicable) Not applicable

The holder ceased to be a substantial holder on 20/7/2020

The previous notice was given to the company on 17/7/2020

The previous notice was dated 17/7/2020

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
15/7/2020	Constellation Immunotherapy Limited	Disposal of fully paid ordinary shares to market	\$3,667.68	Fully paid ordinary shares - 740	740
16/7/2020	Constellation Immunotherapy Limited	Disposal of fully paid ordinary shares to market	\$16,553.27	Fully paid ordinary shares - 3,403	3,403
17/7/2020	Constellation Immunotherapy Limited	Disposal of fully paid ordinary shares to market	\$41,367.12	Fully paid ordinary shares - 8,728	8,728
20/7/2020	Constellation Immunotherapy Limited	Disposal of fully paid ordinary shares to market	\$79,281.08	Fully paid ordinary shares - 19,777	19,777

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	Not applicable

4. Addresses


The addresses of persons named in this form are as follows:

Name	Address
Constellation Immunotherapy Limited	Unit 1233, 12/F, Star House, 3 Salisbury Road, Tsim Sha Tsui, Kowloon, Hong Kong
Everbest City Limited	CCS Trustees Limited, 263 Main Street, Road Town, Tortola, British Virgin Islands
Mr. Fung Yuen Wong	6 Cooper Road, Jardine's Lookout, Hong Kong

Signature

print name FUNG YUEN WONG capacity Director

sign here



date 21/7/2020

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.